The protective effects of lycopus lucidus turcz in diabetic retinopathy and its possible mechanisms

References

• Abu El-Asrar AM, Midena E, Al-Shabrawey M, et al. New developments in the pathophysiology and management of diabetic retinopathy. J Diabetes Res. 2013;2013:1.
   Web of Science ®Google Scholar
• Robinson R, Barathi VA, Chaurasia SS, et al. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech. 2012;5:444–456.
   PubMed Web of Science ®Google Scholar
• Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium. 2002;9:231–238.
   PubMedGoogle Scholar
• Heng LZ, Comyn O, Peto T, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2013;30:640–650.
   PubMed Web of Science ®Google Scholar
• Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363–365.
   PubMed Web of Science ®Google Scholar
• Kastelan S, Tomic M, Gverovic Antunica A, et al. Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm 2013;2013:8.
   Web of Science ®Google Scholar
• Rangasamy S, McGuire PG, Franco Nitta C, et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One. 2014;9:e108508.
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris 3rd FL, Klein, RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682.
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–358.
   PubMed Web of Science ®Google Scholar
• Gologorsky D, Thanos A, Vavvas D. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm. 2012;2012:1.
   Web of Science ®Google Scholar
• Aldebasi YH, Rahmani AH, Khan AA. The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int J Clin Exp Med. 2013;6:239–251.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656–660.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501–509.
   PubMed Web of Science ®Google Scholar
• Liu X, Ye F, Xiong H, et al. IL-1beta induces IL-6 production in retinal Muller cells predominantly through the activation of p38 MAPK/NF-kappaB signaling pathway. Exp Cell Res. 2015;331:223–231.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lai D, Bao S, et al. Triamcinolone acetonide inhibits p38MAPK activation and neuronal apoptosis in early diabetic retinopathy. CMM. 2013;13:946–958.
   PubMed Web of Science ®Google Scholar
• Cai Y, Li W, Tu H, et al. Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-kappa B signaling. Bioorg Med Chem Lett. 2017;27:1835–1839.
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249–1256.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Kang DG, Kim JS, et al. Lycopus lucidus inhibits high glucose-induced vascular inflammation in human umbilical vein endothelial cells. Vascul Pharmacol. 2008;48:38–46.
   PubMed Web of Science ®Google Scholar
• Yao Y, Yang J, Wang D, et al. The aqueous extract of Lycopus lucidus Turcz ameliorates streptozotocin-induced diabetic renal damage via inhibiting TGF-beta1 signaling pathway. Phytomedicine. 2013;20:1160–1167.
   PubMed Web of Science ®Google Scholar
• Lu YH, Huang JH, Li YC, et al. Variation in nutritional compositions, antioxidant activity and microstructure of Lycopus lucidus Turcz. root at different harvest times. Food Chem. 2015;183:91–100.
   PubMed Web of Science ®Google Scholar
• Elsherbiny NM, Ahmad S, Naime M, et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013;93:78–88.
   PubMed Web of Science ®Google Scholar
• Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol. 2011;12:369–372.
   PubMed Web of Science ®Google Scholar
• Kumar B, Gupta SK, Saxena R, et al. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012;58:132–139.
   PubMed Web of Science ®Google Scholar
• Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond). 2006;20:1366–1369.
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci. 2004;45:4161–4166.
   PubMed Web of Science ®Google Scholar
• Noda K, Nakao S, Ishida S, et al. Leukocyte adhesion molecules in diabetic retinopathy. J Ophthalmol. 2012 ;2012:1.
   Web of Science ®Google Scholar
• Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52–59.
   PubMedGoogle Scholar
• Spranger J, Pfeiffer AF. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2001;109:S438–S50.
   PubMed Web of Science ®Google Scholar
• Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011;89:405–411.
   PubMed Web of Science ®Google Scholar
• Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915–930.
   PubMed Web of Science ®Google Scholar
• Tremolada G, Del Turco C, Lattanzio R, et al. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res. 2012;2012:1.
   Google Scholar
• Abu El-Asrar AM, Mohammad G, Allegaert E, et al. Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy. Mol Vis. 2018;24:394–406.
   PubMed Web of Science ®Google Scholar
• Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes. 2003;52:506–511.
   PubMed Web of Science ®Google Scholar
• Chao HM, Hu L, Cheng JM, et al. Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase. Chin Med. 2016;11:39.
   PubMed Web of Science ®Google Scholar
• Xie MS, Zheng YZ, Huang LB, et al. Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model. Int J Ophthalmol. 2017;10:1824–1829.
   PubMed Web of Science ®Google Scholar
• Li Y, Bai YJ, Jiang YR, et al. Apelin-13 is an early promoter of cytoskeleton and tight junction in diabetic macular edema via PI-3K/Akt and MAPK/Erk signaling pathways. Biomed Res Int. 2018;2018:3242574.
   PubMed Web of Science ®Google Scholar